PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.
Continued strong financial results and cash generation, achieving all 2025 guidance metrics Full year earnings growth; GAAP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results